Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-ATACT: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic thyroid cancer
2022-001908-17Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2022
- Countries
- 1
01
Overview
A Phase 2 trial of 6MHP vaccine + dabrafenib + trametinib in anaplastic thyroid cancer (ATC), sponsored by Leiden University Medical Center. Started Jul 2022; status: active.
02
Drugs
6MHP vaccine + dabrafenib + trametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on 2022-001908-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001908-17.